InThought Labs builds JP Morgan Conference AI to cut through the hype

Forget their takeaways. Get Yours!

330+ companies presented at JPM 2025. Everyone’s writing what they noticed. We built a way to answer what you want to know.

Why we built this

JPM produces hundreds of hours of content. Most “analysis” you’ll read reflects what one person happened to see – filtered through what they already believed. We wanted to ask better questions and let the data answer. So we took a different approach: compile everything, make it queryable, let our analysts ask questions across the entire dataset.

Now we’re sharing that capability with you.

For example, one of our analysts posed:

“Which therapeutic areas have no effective treatments and first-mover potential?”

Our AI provided:

Friedreich’s Ataxia and several neuro indications emerged as underserved whitespace.
Or:

“How are companies actually deploying AI?”

And the response?:

A clear pattern: the biggest wins aren’t in the lab, they’re in operations and commercial functions where data infrastructure is more mature.

Here’s your chance to craft the query.

These aren’t insights you get from attending sessions. They’re insights you get from querying the whole picture.

Our consulting team at inThought is using this for client work. But we’re opening it up—ask us your JPM questions and we’ll run them for free.

Dr. D’Imperio joined inThought in 2021, bringing years of experience in pharmaceutical industry, academia and clinical practice. Dr. D’Imperio held various positions within Medical Affairs functions for both small and large biopharmaceutical companies, including Senior Manager of Medical Information, Pharmacovigilance and US/EU Regulatory reporting, product labeling, clinical trial management, and most recently, field-based Medical/Scientific Liaison.

Contact us

Learn how inThought Labs can simplify your life and empower your team with expert consultants and our cloud-based system, inVision.

Chris Martin

President

As the president of inThought Labs, Chris is focused on constantly improving inVision, the leading competitive and market intelligence platform for the biopharmaceutical industry, to better meet the changing needs of clients.

 

With 20 years of experience in roles being a consumer of market and competitive information, Chris understands the needs and priorities of clients. Chris was a senior principal and co-founder of inThought, a life science consulting, market research, and analytics firm. Collaborating with Ben Weintraub, Chris also co-founded BiotechTracker, an online tool for investors and precursor to inVision. Previous to inThought, he was a healthcare analyst and co-portfolio manager at two investment firms. Chris served in health care policy roles at the White House Office of Management and Budget. These roles included Medicare Desk Officer at the Office of Information and Regulatory Affairs, where he was responsible for providing recommendations to senior White House policy officials on healthcare policies and regulations.

 

Chris has a Master in Business Administration from Harvard Business School, a Master in Engineering from Villanova University, and a Bachelor of Science in Engineering from Cornell University. Prior to attending Harvard Business School, Chris served on two U.S. Navy nuclear submarines and at the Pentagon.